Abstract
Background
Despite major advances, multiple myeloma remains an incurable disease. Epidemiological data from high-quality population-based registries are needed to understand the heterogeneous landscape of the disease.
Methods
Incidence, mortality and survival in multiple myeloma were comprehensively analyzed in the Girona and Granada population-based cancer registries, over a 23-year study (1994–2016), divided into three periods (1994–2001, 2002–2009 and 2010–2016). Joinpoint regression analysis was used to estimate the annual percentage change in incidence and mortality. Age-standardized net survival was calculated with the Pohar–Perme method.
Results
1957 myeloma patients were included in the study, with a median age of 72 years. Age-standardized incidence and mortality rates decreased over time in both sexes and both rates were higher in males. Five-year age-standardized net survival by period was 27.4% (1994–2001), 38.8% (2002–2009), and 47.4% (2010–2016). Survival improved for all age groups: 32.4%, 74.1% and 78.5% for patients aged 15–49; 27.5%, 44.6%, and 58.5% for those aged 50–69; finally, 24.8%, 25.5%, and 26.3% for the older group.
Conclusion
Incidence remained overall stable throughout the study, with only a small increase for men. Mortality was progressively decreasing in both sexes. Both incidence and mortality were higher in men. Age plays a critical role in survival, with impressive improvement in patients younger than 70 years, but only a minor benefit in those older than 70.
Similar content being viewed by others
References
Swerdlow SH, Campo E, Pileri SA, Lee N, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569.
Rajkumar SV, Dimopoulos MA, Palumbo A, Bladé J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5.
Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R and Ferlay J, editors (2017) Cancer Incidence in Five Continents, Vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Available from: http://ci5.iarc.fr, (Accessed 9 Dec 2017)
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñero M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–53. https://doi.org/10.1002/ijc.31937.
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma. A systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221–7.
Galceran J, Amejide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19(7):799–825. https://doi.org/10.1007/s12094-016-1607-9.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Ca Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.213590.
Ludwig H, Novis S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the Globe; interrelations between health access and quality, economic resources, and patient empowerment. Oncologist. 2020. https://doi.org/10.1634/theoncologist.2020-0141.
Ríos-Tamayo R, Sánchez D, Chang-Chan DY, Sánchez MJ. Epidemiology of multiple myeloma. In: Al-Anazi KA, editor. Update on multiple myeloma. London: Intech; 2018.
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15(1):23–34.
Ríos-Tamayo R, Sánchez MJ, Puerta JM, Sainz J, Chang-Chan DY, Rodríguez T, et al. Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. Cancer Epidemiol. 2015;39(5):693–9. https://doi.org/10.1016/j.canep.2015.08.002.
Villavicencio A, Solans M, Auñón-Sanz C, Roncero JM, Marcos-Gragera R. Population-based survival of lymphoid neoplasms: twenty years of epidemiological data in the Girona province. Spain Cancer Epidemiol. 2020. https://doi.org/10.1016/j.canep.2020.101841.
Ríos-Tamayo R, Sainz J, Martínez-López J, Puerta JM, Chang-Chan DY, Rodríguez T, et al. Early mortality in multiple myeloma: the time-dependent impact of comorbidity: a population-based study in 621 real-life patients. Am J Hematol. 2016;91(7):700–4. https://doi.org/10.1002/ajh.24389.
Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1(4):282–7. https://doi.org/10.1182/bloodadvances.2016002493.
Blimark CH, Turesson I, Genell A, Ahlberg L, Björkstrand B, Carlson K, et al. Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018;103(3):506–13. https://doi.org/10.3324/haematol.2017.178103.
Andres M, Feller A, Arndt V, the NICER Working Group. Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013. Cancer Epidemiol. 2018;53(4):105–10. https://doi.org/10.1016/j.canep.2018.01.015.
Sneyd MJ, Cox B, Morison IM. Trends in myeloma incidence, mortality and survival in New Zealand (1985–2016). Cancer Epidemiol. 2019;60(6):55–9. https://doi.org/10.1016/j.canep.2019.03.006.
Solans M, Fàbrega A, Morea D, Auñon-Sanz C, Granada I, Roncero JM, et al. Population-based incidence of lymphoid neoplasms: twenty years of epidemiological data in the Girona province. Spain Cancer Epidemiol. 2019;58(2):8–11. https://doi.org/10.1016/j.canep.2018.11.001.
Bora K. Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography. Cancer Epidemiol. 2019;59(4):215–20. https://doi.org/10.1016/j.canep.2019.02.010.
Tsang M, Le M, Ghazawi FM, Cyr J, Alakel A, Rahme E, et al. Multiple myeloma epidemiology and patient geographic distribution in Canada: a population study. Cancer. 2019;125(14):2435–44. https://doi.org/10.1002/cncr.32128.
Latifi-Pupovci H, Selmonaj M, Ahmetah-Shala B, Dushi M, Grajqevci V. Incidence of haematological malignancies in Kosovo. A post “uranium war” concern. PLoS ONE. 2020;15:0232063. https://doi.org/10.1371/journal.pone.0232063.
Wang S, Xu L, Feng J, Liu Y, Liu L, Wang J, et al. Prevalence and Incidence of multiple myeloma in urban area in China: A national population-based analysis. Front Oncol. 2020;9:1513. https://doi.org/10.3389/fonc.2019.01513.
Langseth ØO, Myklebust TÅ, Johannesen TB, Hjertner Ø, Waage A. Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982–2017. Br J Haematol. 2020;191(3):418–517. https://doi.org/10.1111/bjh.16674.
Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018;8:26. https://doi.org/10.1038/s41408-018-0065-8.
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–67. https://doi.org/10.1002/ajh.25791.
Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94. https://doi.org/10.1038/s41408-020-00359-2.
Richardson PG, San Miguel J, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109. https://doi.org/10.1038/s41408-018-0141-0.
Mai EK, Haas EM, Lücke S, Löpprich M, Kunz C, Pritsch M, et al. A systematic classification of death causes in multiple myeloma. Blood Cancer J. 2018;8:30. https://doi.org/10.1038/s41408-018-0068-5.
Mohty M, Cavo M, Fink L, Gonzalez-McQuire S, Leleu H, Mateos MV, et al. Understanding mortality in multiple myeloma: findings of a European retrospective chart review. Eur J Haematol. 2019;103(2):107–15. https://doi.org/10.1111/ejh.13264.
Liu W, Liu J, Song Y, Wang X, Zhou M, Wang L, et al. Mortality of lymphoma and myeloma in China, 2004–2017: an observational study. J Hematol Oncol. 2019;12:22. https://doi.org/10.1186/s13045-019-0706-9.
Castañeda-Avila MA, Ortiz-Ortiz KJ, Torres-Cintrón CR, Birmann BM, Epstein MM. Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987–2013. Int J Cancer. 2020;146(1):35–43. https://doi.org/10.1002/ijc.32232.
Ríos-Tamayo R, Sainz J, Puerta JM, Romero A, González PA, López P, et al. The role of diagnostic delay in multiple myeloma: “A delay paradox.” Haematologica. 2015;100(s1):510.
Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, et al. Time from first symptom onset to the final diagnosis of multiple myeloma (MM)-possible risks and future solutions: retrospective and prospective ‘Deutsche Studiengruppe MM’ (DSMM) and ‘European Myeloma Network? (EMN) analysis. Leuk Lymphoma. 2020;61(4):875–86. https://doi.org/10.1080/10428194.2019.1695051.
Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10:56. https://doi.org/10.1038/s41408-020-0323-4.
Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I, et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica. 2018;103:e412. https://doi.org/10.3324/haematol.2017.183475.
Turesson I, Bjorkholm M, Blimark CH, Kristinson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101(2):237–44. https://doi.org/10.1111/ejh.13083.
Howell D, Smith A, Appleton S, Bagguley T, Macleod U, Cook G, Patmore R, et al. Multiple myeloma: routes to diagnosis, clinical characteristics and survival – findings from a UK population-based study. Br J Haematol. 2017;177(1):67–71. https://doi.org/10.1111/bjh.14513.
Hsieh RW, Go RS, Abeykoon JP, Kapoor P, Kumar SK, Gertz MA, et al. Characteristics of long-term survivors with multiple myeloma: a national cancer data base analysis. Cancer. 2019;125(20):3574–81. https://doi.org/10.1002/cncr.32357.
Weil C, Gelerstein S, Moser SS, Chodick G, Ben-David NB, Shalev V, et al. Real-world epidemiology, treatment patterns and survival of multiple myeloma patients in a large nationwide health plan. Leuk Res. 2019;85(10):106219. https://doi.org/10.1016/j.leukres.2019.106219.
Çiftçiler R, Göker H, Demiroglu H, Aksu S, Saynalp N, Haznedaroglu IC, et al. Evaluation of the survival outcomes of multiple myeloma patients according to their plasmacytoma presentation at diagnosis. Turk J Hematol. 2020;37(4):256–62. https://doi.org/10.4274/tjh.galenos.2019.2019.0061.
Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132–41. https://doi.org/10.1016/S0140-6736(19)32956-3.
Çiftçiler R, Göker H, Buyukasik Y, Saynalp N, Haznedaroglu IC, Aksu S, et al. Comparison of bortezomib-cyclophosphamide-dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. Hematol Rep. 2020;12:8267. https://doi.org/10.4081/hr.2020.8267.
Göker H, Çiftçiler R, Demiroglu H, Turgut M, Saynalp N, Haznedaroglu IC, et al. Predictive factors for stem cell mobilization failure in multiple myeloma patients: a single center experience. Transfus Apher Sci. 2020;59(1):102595. https://doi.org/10.1016/j.transci.2019.06.023.
Demiroglu H, Çiftçiler R, Buyukasik Y, Göker H. Prediction of stem cell mobilization failure in patients with Hodgkin and non-Hodgkin lymphoma. Turk J Hematol. 2020. https://doi.org/10.4274/tjh.galenos.2020.2020.0409.
Afshar N, English DR, Blakely T, Thusfield V, Farrugia H, Giles GG, et al. Differences in cancer survival by area-level socio-economic disadvantage: a population-based study using cancer registry data. PLoS ONE. 2020;15:e0228551. https://doi.org/10.1371/journal.pone.0228551.
Acknowledgments
The authors acknowledge with gratitude to Eva Ríos Sánchez the English revision of the manuscript. This paper is part of the doctoral thesis of Daysi Yoe-Ling Chang Chang, first author of the paper, in the context of the Inter-University Health Sciences Doctoral Program offered jointly by the University of Sevilla, the University of Jaen, and the Andalusian School of Public Health.
Funding
This research received no external funding.
Author information
Authors and Affiliations
Contributions
All authors provided substantial contributions in the acquisition, analysis or interpretation of data. All authors revised the article at any stage and finally approved the version to be published.
Corresponding author
Ethics declarations
Conflicts of interest
R.R.-T has received research support and honoraria as speaking fee from Amgen, Celgene, Janssen and Takeda. The rest of the authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Chang-Chan, DYL., Ríos-Tamayo, R., Rodríguez Barranco, M. et al. Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study. Clin Transl Oncol 23, 1429–1439 (2021). https://doi.org/10.1007/s12094-020-02541-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-020-02541-1